Miragen Therapeutics, Inc. (NYSE:MGEN)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen and Company in a research report issued to clients and investors on Monday.

The analysts wrote, “MGEN reported 3Q and provided an overview of recent progress and upcoming.””

ILLEGAL ACTIVITY WARNING: “Cowen and Company Reaffirms “Buy” Rating for Miragen Therapeutics, Inc. (MGEN)” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/13/cowen-and-company-reaffirms-buy-rating-for-miragen-therapeutics-inc-mgen.html.

Receive News & Ratings for Miragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.